Research programme: HIV-1 entry inhibitors - Bristol-Myers Squibb

Drug Profile

Research programme: HIV-1 entry inhibitors - Bristol-Myers Squibb

Alternative Names: AI806; BMS-378806; BMS-806; HIV-1 entry inhibitor - Bristol-Myers Squibb

Latest Information Update: 15 Jul 2015

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antivirals; Benzamides; Indoles; Small molecules
  • Mechanism of Action HIV envelope protein gp120 inhibitors; HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 22 Dec 2010 Preclinical development is ongoing in USA
  • 31 Oct 2005 BMS 806 has been licensed to the International Partnership for Microbicides worldwide
  • 08 Oct 2003 A preclinical study has been added to the adverse events and pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top